Patients with TNBC have the worst prognosis and mortality risk in five years than other subtypes of breast cancer and cannot benefit from hormone- or trastuzumab-based therapy because of the loss of target receptors such as ER, PR, and HER-2 [5]. This evidence concerns the gene ESR1 and breast carcinoma.